- COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Accessed May 6, 2022. https://www.covid19treatmentguidelines.nih.gov/critical-care.
- Therapeutics and COVID-19. World Health Organization. Accessed May 6, 2022. https://apps.who.int/iris/bitstream/handle/10665/345356/WHO-2019-nCoV-therapeutics-2021.3-eng.pdf.
- Waleed A, Laura E, Fayez A, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e234. doi:10.1097/CCM.0000000000004899.
- Tenforde M, Self W, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043–2054. doi:10.1001/jama.2021.19499.
- Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: a systematic review. World J Crit Care Med. 2021;10(4):132–150. doi:10.5492/wjccm.v10.i4.132.
- Roesch T, Rodriguez L. A review of the currently available monoclonal antibodies for COVID-19. Contagion. 2021;6(5):8–9.
- Center for Biologics Evaluation and Research. COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. Guidance for Industry. Silver Spring, MD: Food and Drug Administration; February 2021. https://www.fda.gov/media/137926/download.
- Mollan KR, Eron JJ, Krajewski TJ, et al. Infectious SARS-CoV-2 virus in symptomatic COVID-19 outpatients: host, disease, and viral correlates. Clinical Infectious Diseases, ciab968. doi:10.1093/cid/ciab968.
- Weinreich D, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021;384(3):238–251. doi:10.1056/NEJMoa2035002.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi:10.1056/NEJMoa2108163.
- ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, et al. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2021;384:905–914.
- Lundgren JD, Grund B, Barkauskas CE, et al; ACTIV-3/TICO Bamlanivimab Study Group. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann Intern Med. 2022;175(2):234–243. doi:10.7326/M21-3507.
- RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10325):665–676. doi:10.1016/S0140-6736(22)00163-5.
- Frediansyah A, Nainu F, Dhama K, et al. Remdesivir and its antiviral activity against COVID-19: a systematic review. Clin Epidemiol Glob Health. 2021;9:123–127. doi:10.1016/j.cegh.2020.07.011.
- Gottlieb R, Vaca C, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386(4):305–315. doi:10.1056/NEJMoa2116846.
- Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456. doi:10.1016/j.cell.2021.12.032.
- Gilead Sciences. Gilead statement on Veklury (remdesivir) and the SARS-CoV-2 Omicron variant. December 1, 2021. https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-veklury-remdesivir-and-the-sars-cov-2-omicron-variant.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 5
Case Studies
Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir
Vivek K. Katariaa Department of Pharmacy, Baylor University Medical Center, Dallas, Texas
https://orcid.org/0000-0003-1149-5937
, PharmDhttps://orcid.org/0000-0003-1149-5937, Mezgebe Berheb North Texas Infectious Disease Consultants, Baylor University Medical Center, Dallas, Texashttps://orcid.org/0000-0002-7287-567X
, MD, MPHhttps://orcid.org/0000-0002-7287-567X & Uriel Sandkovskyb North Texas Infectious Disease Consultants, Baylor University Medical Center, Dallas, TexasCorrespondence[email protected]
https://orcid.org/0000-0001-9077-3426
, MD, MShttps://orcid.org/0000-0001-9077-3426